Delivering New Promise for Early Stage Colon Cancer Patients


About ColoPrint® for Stage II & III Colon Cancer Prognosis and Prediction

ColoPrint is a microarray-based gene expression profile for predicting the distant recurrence of stage II and III colon cancer patients.  Currently in the final stage of development, the combination of this profile and selected clinical variables could prove even more powerful and accurate in identifying high risk patients for more personalized clinical management. 


ColoPrint and the PARSC Clinical Trial for Colon Cancer

The PARSC (Prospective Analysis of Risk Stratification by ColoPrint) Trial is a multi-center, multi-national, prospective study for the assessment of recurrence risk in Stage II and III Colon Cancer patients.  This study will address the feasibility and quality assurance of the ColoPrint gene expression profile in clinical practice.  ColoPrint risk assessment results will be compared to the risk assessment resulting from various clinical parameters following local/ASCO criteria and independent investigator criteria.


Objectives

  1. Organization and controlled implementation of ColoPrint for prognosis and prediction.
  2. The prospective comparison of the ColoPrint recurrence risk signature versus clinical parameters based on local protocol and ASCO high-risk recommendations, which account for the presence of at least one of the following: T4, perforation/ obstruction, G3, and inadequate node sampling (less than 12 nodes).
  3. Validation of the ColoPrint gene expression profile as a powerful and clinically useful prognostic tool for recurrence risk assessment in comparison to traditional clinical risk factors for accurate prediction of the 3 year relapse rate.
  4. To assess the proportion of ‘good prognosis profile’ and ‘poor prognosis profile’ in stage II colon cancer patients in the two ColoPrint risk categories in different ethnic populations and in different countries.
  5. Measure how ColoPrint results alter clinical treatment decisions.


Criteria

Inclusion criteria

  • Age ≥ 18 years
  • Adenocarcinoma of the colon
  • Stage I, II, III, planned to be treated with radical surgery

 

Exclusion Criteria

  • Prior malignancy with the exception of basal cell carcinoma or cervical dysplasia
  • Any neo-adjuvant therapy
  • Synchronous tumors


For additional information on Agendia’s PARSC clinical trial please visit ClinicalTrials.Gov: Colon Cancer Clinical Trial

For more information on participation in Agendia's PARSC clinical trial, please contact Agendia Clinical Trials.

References
  1. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK (eds) (2005) . SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site, 2006.
  2. Coleman MP, Rachet B, Woods LM, Mitry E, Riga M, Cooper N, Quinn MJ, Brenner H, Esteve J. (2004) Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br J Cancer 90 :1367-73.
  3. van Cutsem EJ, Kataja VV, ESMO GuidelinesTask Force (2005) ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer. Ann Oncol. 16 Suppl 1:i16-7
  4. Benson AB, Schrag D, Sommerfield MR et al. (2004) ASCO recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408-19
  5. Sobrero A and Koehne CH. (2006) Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Lancet Oncol 7:515-17
  6. 6)    Andre T, Sargent D, Tabernero J. et al. (2006) Current Issues in Adjuvant Treatment of Stage II Colon Cancer. Ann. Surg. Oncol. 13;887-98
  7. Eschrich S, Yang I, Bloom G et al. (2005) Molecular Staging for Survival Predication of Colorectal Cancer Patients. JCO 15;3526-35
  8. Barrier A, Boelle PY, Roser F et al. (2006) Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol. 24(29):4685-91
  9. Lin YH, Friederichs J, Black MA et al. (2007) Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res. 13.498-507
  10. van 't Veer LJ, Dai H, van de Vijver MJ et al. (2002): Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536
  11. Buyse M, Loi S, van't Veer LJ et al. (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst. 98(17):1183-92
  12. Glas AM, Floore A, Delahaye LJ et al. (2006) Converting a breast cancer microarray signature into a high-throughput diagnostic test.  BMC Genomics. 2006 Oct 30;7:278